大剂量三苯氧胺逆转治疗对NP方案耐药的晚期非小细胞肺癌的临床观察  

Clinical observation on reverse treatment of large dose Tamoxifen in non-small cell lung cancer patients treated with vinorebin-cisplatin regimen

作　　者：陈日新[1] 廖勇 逯华[1] 伍美娟[1] 

机构地区：[1]柳州市人民医院肿瘤科,广西柳州545001 [2]广西龙潭医院外一科,广西柳州545005

出　　处：《华夏医学》2005年第4期522-524,共3页Acta Medicinae Sinica

摘　　要：目的:观察大剂量三苯氧胺(Tamoxifen,TAM)逆转治疗对NP方案(去甲长春碱+顺铂)耐药的晚期非小细胞肺癌(NSCLC)的疗效和不良反应.方法:经NP方案化疗2个周期以上,复查均复发或进展的32例晚期NSCLC患者,加用TAM 240mg/d,第1～8天,并继续原方案化疗2个周期以上.结果:CR1例,PR12例,SD15例,PD4例,总有效率(CR+PR)40.6%%(13/32),中位生存期为10个月,半年、1年生存率分别为65.6%(21/32)、37.5%(12/32),中位肿瘤进展时间8个月.不良反应主要是恶心呕吐、白细胞减少和周围神经毒性,经对症止吐、升白细胞等处理后均恢复正常.结论:采用大剂量TAM能逆转治疗对NP方案产生耐药的晚期NSCLC,而且安全、经济,值得进一步研究.Objective ：To observe the effect and toxicity of Tamoxifen（TAM） reverse treatment in non-small cell lung cancer （NSCLC） patient with Vinorelbin-Cisplatin（NP） regimen. Methods： After NP regimen treatment, 32 advance NSCLC patients were found tumor recurrence. These patients were administered TAM 240mg/day for 1-8 days ,and continued NP regimen more than 2 periods. Results：l patient was completely remission （CR）, 12 patients were partial remission （PR）, 15 patients were stable disease （SD） and 4 patients were progression （PD）. A overall response rate （CR ＋PR） was 40. 6%（13/32）,a median survival time was 10 months, 0. 5-,1-year survival were 65.5%（21/32）,37.5% （ 12/32） ,a median tumor advance time was 8 months. The main toxic reaction were nausea, emesis, leukopenia and peripheral nerve toxicity. All patients were recovered after antiemetic and leukogenic treatment. Conclusion：Large dose TAM can reverse multidrug resistance in NSCLC patients with NP regimen,the method is safe and economical.

关 键 词：非小细胞肺癌 三苯氧胺 多药耐药性 化学治疗 逆转治疗 

分 类 号：R734.2[医药卫生—肿瘤]